Biotech

All Articles

AstraZeneca articles data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early take a look at the efficiency of its internal antibody-drug con...

iTeos- GSK's TIGIT celebrity presents meaningful enhancement

.After revealing a phase 3 launch based upon positive midstage outcomes, iTeos and also GSK are ulti...

More collective FDA can easily speed up rare illness R&ampD: record

.The FDA should be extra open as well as joint to discharge a rise in approvals of unusual condition...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It's an extraordinarily active Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Rehabs...

Atea's COVID antiviral fails to stop hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has neglected yet another COVID-19 trial, yet the biotech still kee...

Neurocrine's bid to spare schizophrenia possibility fails

.Neurocrine Biosciences' schizophrenia course pivot has stopped working. The biotech was unable to d...

Sanofi pays for $110M upfront for late-stage radioligand treatment

.Sanofi has actually made an overdue entry to the radioligand gathering, spending 100 thousand euros...

F 2G increases $100M for second try to get brand-new antifungal to market

.After F2G's 1st effort to receive a new training class of antifungal to market was derailed by the ...

Moderna targets $1.1 B in R&ampD investing slices, drops 5 systems amidst productivity stress

.Moderna has promised to reduce R&ampD spending by $1.1 billion by 2027. The decision to shrink the ...

Sanofi's $80M bet on Key dystrophy medication finishes in phase 3 fail

.Just four months after Sanofi wager $80 million in beforehand cash money on Key Rehabs' losmapimod,...